Changes in Hong Kong stocks | US-China Jiahe (02453) opened more than 6% of its subsidiary Guangzhou Taihe Cancer Hospital approved for the “Hong Kong and Macau Pharmaceutical Connect” list of designated medical institutions

The Zhitong Finance App learned that the US and China Jiahe (02453) opened more than 6% higher. As of press release, it rose 6.12% to HK$2.08, with a turnover of HK$107,700.

According to the news, the US and China Jiahe announced that on December 8, 2025, Guangzhou Taihe Cancer Hospital, a subsidiary of the company, was approved by the Guangdong Provincial Health Commission and the Guangdong Drug Administration to enter the list of designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area.

The “Hong Kong-Macao Pharmaceutical Device Connect” is the core implementation initiative of the “Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical and Medical Device Supervision, Innovation and Development Work Plan”. Designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area can import and use the Guangdong-Hong Kong-Macao Greater Bay Area special pharmaceutical policy with approval, allowing designated medical institutions to use clinically urgently needed drugs and advanced medical devices already marketed in Hong Kong and Macao with approval.

This accreditation has made the company a professional oncology medical institution qualified to use innovative pharmaceutical devices in Hong Kong and Macau. The company can take the lead in introducing and using urgently needed drugs in the field of oncology that have already been listed in Hong Kong and Macau in China and have not yet been approved in China, including novel original research drugs, etc., to further broaden business boundaries, form a differentiated competitive advantage with the market, provide more cancer patients with urgently needed drugs, and strengthen the company's competitive advantage in the field of oncology medicine.